VYGR News and Press, Voyager Therapeutics Inc. From 09/02/25

2025-09-02 18:23:41 ET Voyager Therapeutics, Inc. (VYGR) Citi's Biopharma Back to School Conference September 2, 2025 4:00 PM EDT... Read the full article on Seeking Alpha For further details see: Voyager Therapeutics, Inc. (VYGR) Presents At Citi's Biopharma Back To School ...

LEXINGTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences: Citi's ...

2025-08-06 17:20:19 ET More on Voyager Therapeutics Voyager Therapeutics: Navigating AAV Headwinds And A Long Road For VY7523 (Downgrade) Seeking Alpha’s Quant Rating on Voyager Therapeutics Historical earnings data for Voyager Therapeutics Financial i...

- Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to pipeline; fourth asset in industry-leading Alzheimer’s disease franchise - - 11 partnered programs with potential for $2.6B in development-stage milest...

SOPHiA GENETICS SA (SOPH) is expected to report for Q2 2025 Investors Title Company (ITIC) is expected to report for Q2 2025 Safehold Inc. (SAFE) is expected to report $0.39 for Q2 2025 First Guaranty Bancshares Inc. (FGBI) is expected to report $-0.2 for Q2 2025 United Fire Group...

Voyager Therapeutics Inc. (VYGR) is expected to report $-0.48 for Q2 2025

- New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant - - Voyager’s wholly-owned Alzheimer’s disease franchise now includes clinical-stage a...

LEXINGTON, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager, and additional members ...

2025-06-06 17:02:27 ET Introduction My last look at Voyager Therapeutics ( VYGR ) was September 2023. Voyager was developing a one-and-done Alzheimer’s gene therapy treatment. It was still seeking an IND, with a target in the first half of 2024. Moreover, partnerships...

LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced the first peer-reviewed publication of data demonstrating the ability of alkaline phosphatase (ALP...